MYDA Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

MYDA Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,407	Closed	-$118K	–	198
2017 Q4	$118K	Buy	+1,407	New	+$138K	0.05%	139

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MYDA Advisors's BLCM Position: Q1 2018 in Review

MYDA Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2018, closing a stake of 1,407 shares — an estimated $118K sold.

MYDA Advisors first reported a position in BLCM in Q4 2017 and held it in 1 quarter. The position peaked at $118K in Q4 2017. 90 funds tracked by Wall St. Rank hold BLCM as of Q1 2018.

MYDA Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
MYDA Advisors sold 1,407 Bellicum Pharmaceuticals, Inc. shares in Q1 2018, an estimated $118K.
MYDA Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
MYDA Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $118K in Q4 2017.
90 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2018.

Based on MYDA Advisors's 13F filing for Q1 2018, filed 10 May 2018.